Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Common Equity (2022 - 2025)

Taysha Gene Therapies' Common Equity history spans 4 years, with the latest figure at $219.0 million for Q3 2025.

  • For Q3 2025, Common Equity rose 146.62% year-over-year to $219.0 million; the TTM value through Sep 2025 reached $219.0 million, up 146.62%, while the annual FY2024 figure was $71.5 million, 4.55% down from the prior year.
  • Common Equity for Q3 2025 was $219.0 million at Taysha Gene Therapies, down from $248.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $248.7 million in Q2 2025 and bottomed at -$49.1 million in Q3 2023.
  • The 4-year median for Common Equity is $53.8 million (2024), against an average of $61.0 million.
  • The largest YoY upside for Common Equity was 7796.42% in 2023 against a maximum downside of 558.88% in 2023.
  • A 4-year view of Common Equity shows it stood at $949000.0 in 2022, then skyrocketed by 7796.42% to $74.9 million in 2023, then dropped by 4.55% to $71.5 million in 2024, then soared by 206.17% to $219.0 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Common Equity are $219.0 million (Q3 2025), $248.7 million (Q2 2025), and $55.1 million (Q1 2025).